The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain

Abstract Objective To clarify the distribution of lorlatinib in the brain and elucidate the molecular mechanisms of lorlatinib penetration across the blood‐brain barrier (BBB). Methods Cytological experiments were performed to investigate the growth inhibitory effect of lorlatinib on different cells...

Full description

Bibliographic Details
Main Authors:	Wei Chen, Dujia Jin, Yafei Shi, Yujun Zhang, Haiyan Zhou, Guohui Li
Format:	Article
Language:	English
Published:	Wiley 2020-06-01
Series:	Cancer Medicine
Subjects:	blood‐brain barrier Crizotinib Lorlatinib SPP1
Online Access:	https://doi.org/10.1002/cam4.3061

Similar Items

A Comprehensive Analysis of Metabolomics and Transcriptomics Reveals Novel Biomarkers and Mechanistic Insights on Lorlatinib Crosses the Blood-Brain Barrier
by: Wei Chen, et al.
Published: (2021-08-01)

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
by: SiNi Li, et al.
Published: (2021-05-01)

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
by: Xu Feng, et al.
Published: (2020-10-01)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
by: Ryo Toyozawa, MD, et al.
Published: (2020-06-01)

Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib
by: Stefano Testa, et al.
Published: (2021-06-01)

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
by: Tomoyo Taketa, et al.
Published: (2021-04-01)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
by: Akamine T, et al.
Published: (2018-08-01)

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
by: Sergey V. Orlov, et al.
Published: (2021-08-01)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2021-07-01)

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
by: Passaro A, et al.
Published: (2016-10-01)

Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report
by: Shoko Ueda, et al.
Published: (2021-03-01)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
by: Zhu VW, et al.
Published: (2020-01-01)

Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
by: Takashi Kobayashi, et al.
Published: (2021-08-01)

Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling
by: Yang P, et al.
Published: (2021-03-01)

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
by: Go Makimoto, et al.
Published: (2021-03-01)

Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
by: Liang Dong, et al.
Published: (2018-01-01)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
by: T. Lee Collier PhD, et al.
Published: (2017-10-01)

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review
by: Viola W. Zhu, MD, PhD, et al.
Published: (2021-01-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry
by: Wei Chen, et al.
Published: (2019-01-01)

Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
by: Maximilian J. Hochmair, et al.
Published: (2020-11-01)

Permeability of the Blood-Brain Barrier and Transport of Nanobodies Across the Blood-Brain Barrier
by: Širochmanová I., et al.
Published: (2018-03-01)

Virulence Factors of Meningitis-Causing Bacteria: Enabling Brain Entry across the Blood–Brain Barrier
by: Rosanna Herold, et al.
Published: (2019-10-01)

Passing across the blood-brain barrier in glioblastoma multiforme (GBM)
by: Agata Rocka, et al.
Published: (2020-09-01)

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
by: Sabari JK, et al.
Published: (2017-04-01)

Advancements in the Blood–Brain Barrier Penetrating Nanoplatforms for Brain Related Disease Diagnostics and Therapeutic Applications
by: Suresh Thangudu, et al.
Published: (2020-12-01)

The Potential Roles of Blood–Brain Barrier and Blood–Cerebrospinal Fluid Barrier in Maintaining Brain Manganese Homeostasis
by: Shannon Morgan McCabe, et al.
Published: (2021-05-01)

Established and Emerging Strategies for Drug Delivery Across the Blood-Brain Barrier in Brain Cancer
by: Alessandro Parodi, et al.
Published: (2019-05-01)

The effect of thermal therapy on the blood-brain barrier and blood-tumor barrier
by: Bhuvic Patel, et al.
Published: (2020-07-01)

Metabolite transport across the mammalian and insect brain diffusion barriers
by: Astrid Weiler, et al.
Published: (2017-11-01)

Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine
by: Faisal Mohammad Amin, et al.
Published: (2018-05-01)

In Vitro and In Silico Acetylcholinesterase Inhibitory Activity of Thalictricavine and Canadine and Their Predicted Penetration across the Blood-Brain Barrier
by: Jakub Chlebek, et al.
Published: (2019-04-01)

Remodelling and Treatment of the Blood-Brain Barrier in Glioma
by: Wang Y, et al.
Published: (2021-05-01)

Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier
by: Eurydice Angeli, et al.
Published: (2021-09-01)

Caveolae-Mediated Endothelial Transcytosis across the Blood-Brain Barrier in Acute Ischemic Stroke
by: Min Zhou, et al.
Published: (2021-08-01)

Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation
by: William A. Banks, et al.
Published: (2020-06-01)

Breaching the Blood–Brain Tumor Barrier for Tumor Therapy
by: Fabrizio Marcucci, et al.
Published: (2021-05-01)

Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning
by: Mathieu Nonnenmacher, et al.
Published: (2021-03-01)

Structural aspects of the "blood-brain barrier" area in rat cerebrum
by: Fox, Geoffrey Quentin, 1938-
Published: (1963)

Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood–Brain Barrier
by: Julia V. Georgieva, et al.
Published: (2014-11-01)